Annexon Reports Phase 1 Results For ANX1502, Its Oral Small Molecule Inhibitor Of The Classical ...
(MENAFN - GlobeNewsWire - Nasdaq) Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ... ...
Target Levels Active Drug Achieved Healthy Volunteers Oral Twice Daily Dosing Supportive Impact Pharmacodynamic Biomarker
Source: wn.com